+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Home Imidazoles 1009119-64-5
1009119-64-5,MFCD18074519
Catalog No.:AA00033S
1009119-64-5 | Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester
Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥95%
in stock  
$46.00   $32.00
- +
10mg
≥95%
in stock  
$73.00   $51.00
- +
50mg
≥95%
in stock  
$275.00   $192.00
- +
100mg
≥95%
in stock  
$366.00   $256.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00033S
Chemical Name:
Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester
CAS Number:
1009119-64-5
Molecular Formula:
C40H50N8O6
Molecular Weight:
738.8750
MDL Number:
MFCD18074519
SMILES:
COC(=O)N[[email protected]](C(=O)N1CCC[[email protected]]1c1ncc([nH]1)c1ccc(cc1)c1ccc(cc1)c1cnc([nH]1)[C@@H]1CCCN1C(=O)[[email protected]](C(C)C)NC(=O)OC)C(C)C
Properties
Computed Properties
 
Complexity:
1190  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
4  
Heavy Atom Count:
54  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
4  
Rotatable Bond Count:
13  
XLogP3:
5.1  

Literature

Title: Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100.

Title: David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.

Title: Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.

Title: Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products
1009119-65-6

1009119-65-6
Building Blocks
More >